Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.06
ARNA's Cash-to-Debt is ranked lower than
71% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ARNA: 2.06 )
Ranked among companies with meaningful Cash-to-Debt only.
ARNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46  Med: 3.49 Max: 11204.39
Current: 2.06
0.46
11204.39
Equity-to-Asset 0.44
ARNA's Equity-to-Asset is ranked lower than
73% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARNA: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
ARNA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.49 Max: 0.98
Current: 0.44
0.02
0.98
Debt-to-Equity 0.77
ARNA's Debt-to-Equity is ranked lower than
77% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. ARNA: 0.77 )
Ranked among companies with meaningful Debt-to-Equity only.
ARNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.64 Max: 19.85
Current: 0.77
0
19.85
Debt-to-EBITDA -11.01
ARNA's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ARNA: -11.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ARNA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -17.58  Med: -1.1 Max: 0
Current: -11.01
-17.58
0
Piotroski F-Score: 4
Altman Z-Score: -4.07
Beneish M-Score: -0.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -11.44
ARNA's Operating Margin % is ranked higher than
66% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ARNA: -11.44 )
Ranked among companies with meaningful Operating Margin % only.
ARNA' s Operating Margin % Range Over the Past 10 Years
Min: -2405.23  Med: -432.38 Max: -11.44
Current: -11.44
-2405.23
-11.44
Net Margin % -16.27
ARNA's Net Margin % is ranked higher than
63% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ARNA: -16.27 )
Ranked among companies with meaningful Net Margin % only.
ARNA' s Net Margin % Range Over the Past 10 Years
Min: -2421.99  Med: -525.21 Max: -16.27
Current: -16.27
-2421.99
-16.27
ROE % -57.64
ARNA's ROE % is ranked lower than
60% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ARNA: -57.64 )
Ranked among companies with meaningful ROE % only.
ARNA' s ROE % Range Over the Past 10 Years
Min: -246.16  Med: -132.46 Max: -20.4
Current: -57.64
-246.16
-20.4
ROA % -10.34
ARNA's ROA % is ranked higher than
67% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ARNA: -10.34 )
Ranked among companies with meaningful ROA % only.
ARNA' s ROA % Range Over the Past 10 Years
Min: -65.19  Med: -40.69 Max: -6.47
Current: -10.34
-65.19
-6.47
ROC (Joel Greenblatt) % -26.79
ARNA's ROC (Joel Greenblatt) % is ranked higher than
71% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ARNA: -26.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARNA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -279.74  Med: -109.69 Max: -16.16
Current: -26.79
-279.74
-16.16
3-Year Revenue Growth Rate 11.00
ARNA's 3-Year Revenue Growth Rate is ranked higher than
62% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ARNA: 11.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARNA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -10.6 Max: 35
Current: 11
0
35
3-Year EBITDA Growth Rate 15.00
ARNA's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ARNA: 15.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARNA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.7  Med: -1.45 Max: 74.3
Current: 15
-70.7
74.3
GuruFocus has detected 3 Warning Signs with Arena Pharmaceuticals Inc $ARNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARNA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ARNA Guru Trades in Q3 2016

Jim Simons 6,936,496 sh (+23.84%)
Murray Stahl 45,000 sh (unchged)
Paul Tudor Jones 24,078 sh (-8.11%)
» More
Q4 2016

ARNA Guru Trades in Q4 2016

Paul Tudor Jones 72,259 sh (+200.10%)
Jim Simons 7,522,255 sh (+8.44%)
Murray Stahl 45,000 sh (unchged)
» More
Q1 2017

ARNA Guru Trades in Q1 2017

Joel Greenblatt 37,800 sh (New)
Paul Tudor Jones 141,225 sh (+95.44%)
Jim Simons 8,479,445 sh (+12.72%)
Murray Stahl 45,000 sh (unchged)
» More
Q2 2017

ARNA Guru Trades in Q2 2017

Jim Simons 869,366 sh (+2.53%)
Murray Stahl Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-03-31 New Buy$13.6 - $16.5 $ 26.8581%3,780
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:EPZM, SZSE:300147, SZSE:300363, NAS:AMRN, XPAR:ALCLS, NAS:OMER, SZSE:002604, NAS:ATNX, SZSE:300381, NAS:NDRM, ROCO:4174, XPAR:STAGR, NAS:RGNX, OSTO:HMED, NAS:AMRI, XPAR:GNFT, XMCE:ROVI, NAS:XNCR, NAS:SPPI, SAU:2070 » details
Traded in other countries:RN3N.Germany,
Headquarter Location:USA
Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Top Ranked Articles about Arena Pharmaceuticals Inc

Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017
Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Wall Street Opens Stable With Yellen in 2nd Day of Testimony Yellen expressed confidence in the economy
The three indices are slightly in the green while investors await the second day of testimony from Federal Reserve Board Chair Janet Yellen. Further, Presidents Donald Trump and Emmanuel Macron will shake hands today in Paris. Read more...
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension

Ratios

vs
industry
vs
history
PB Ratio 10.31
ARNA's PB Ratio is ranked lower than
81% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ARNA: 10.31 )
Ranked among companies with meaningful PB Ratio only.
ARNA' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 7.97 Max: 135.77
Current: 10.31
1.23
135.77
PS Ratio 5.60
ARNA's PS Ratio is ranked higher than
70% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ARNA: 5.60 )
Ranked among companies with meaningful PS Ratio only.
ARNA' s PS Ratio Range Over the Past 10 Years
Min: 2.42  Med: 22.82 Max: 85.95
Current: 5.6
2.42
85.95
EV-to-EBIT -70.64
ARNA's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ARNA: -70.64 )
Ranked among companies with meaningful EV-to-EBIT only.
ARNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -117.6  Med: -4.25 Max: -0.6
Current: -70.64
-117.6
-0.6
EV-to-EBITDA -170.71
ARNA's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ARNA: -170.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -350.4  Med: -4.75 Max: -0.8
Current: -170.71
-350.4
-0.8
EV-to-Revenue 8.37
ARNA's EV-to-Revenue is ranked higher than
62% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ARNA: 8.37 )
Ranked among companies with meaningful EV-to-Revenue only.
ARNA' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 17.35 Max: 95
Current: 8.37
2.3
95
Current Ratio 3.21
ARNA's Current Ratio is ranked lower than
59% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ARNA: 3.21 )
Ranked among companies with meaningful Current Ratio only.
ARNA' s Current Ratio Range Over the Past 10 Years
Min: 1.68  Med: 6.36 Max: 91.72
Current: 3.21
1.68
91.72
Quick Ratio 3.05
ARNA's Quick Ratio is ranked lower than
57% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ARNA: 3.05 )
Ranked among companies with meaningful Quick Ratio only.
ARNA' s Quick Ratio Range Over the Past 10 Years
Min: 1.68  Med: 6.36 Max: 91.72
Current: 3.05
1.68
91.72
Days Inventory 195.11
ARNA's Days Inventory is ranked lower than
69% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. ARNA: 195.11 )
Ranked among companies with meaningful Days Inventory only.
ARNA' s Days Inventory Range Over the Past 10 Years
Min: 192.84  Med: 301.17 Max: 555.68
Current: 195.11
192.84
555.68
Days Sales Outstanding 7.45
ARNA's Days Sales Outstanding is ranked higher than
91% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ARNA: 7.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARNA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.45  Med: 48.63 Max: 76.88
Current: 7.45
7.45
76.88
Days Payable 35.56
ARNA's Days Payable is ranked lower than
65% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. ARNA: 35.56 )
Ranked among companies with meaningful Days Payable only.
ARNA' s Days Payable Range Over the Past 10 Years
Min: 35.56  Med: 138 Max: 386.18
Current: 35.56
35.56
386.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.60
ARNA's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ARNA: -3.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARNA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -205.3  Med: -20.3 Max: 1.2
Current: -3.6
-205.3
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 35.33
ARNA's Price-to-Net-Cash is ranked lower than
86% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ARNA: 35.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ARNA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.82  Med: 3.06 Max: 136.56
Current: 35.33
0.82
136.56
Price-to-Net-Current-Asset-Value 23.15
ARNA's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ARNA: 23.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARNA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.78  Med: 3.14 Max: 1462.5
Current: 23.15
0.78
1462.5
Price-to-Tangible-Book 10.53
ARNA's Price-to-Tangible-Book is ranked lower than
74% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ARNA: 10.53 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARNA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62  Med: 3.23 Max: 70.08
Current: 10.53
0.62
70.08
Price-to-Median-PS-Value 0.25
ARNA's Price-to-Median-PS-Value is ranked higher than
91% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ARNA: 0.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARNA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.73 Max: 6.72
Current: 0.25
0.12
6.72
Earnings Yield (Greenblatt) % -1.41
ARNA's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ARNA: -1.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -154.4  Med: -23.5 Max: -0.9
Current: -1.41
-154.4
-0.9

More Statistics

Revenue (TTM) (Mil) $117.73
EPS (TTM) $ -0.57
Beta2.25
Short Percentage of Float10.90%
52-Week Range $11.30 - 27.86
Shares Outstanding (Mil)39.22

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -2.50 -2.16
EPS without NRI ($) -2.50 -2.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}